LGM
STRO icon

Logos Global Management’s Sutro Biopharma STRO Stock Holding History

Logos Global Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-36,195
Closed -$2.81M – 58
2020
Q2 		$2.81M Buy
+36,195
New +$3.47M 0.56% 38

Other funds holding STRO

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Logos Global Management's STRO Position: Q3 2020 in Review

Logos Global Management sold out of Sutro Biopharma (STRO) in Q3 2020, closing a stake of 36,195 shares — an estimated $2.81M sold.

Logos Global Management first reported a position in STRO in Q2 2020 and held it in 1 quarter. The position peaked at $2.81M in Q2 2020. 86 funds tracked by Wall St. Rank hold STRO as of Q3 2020.

  • Logos Global Management reported no remaining Sutro Biopharma position as of Q3 2020 after selling out during the quarter.
  • Logos Global Management sold 36,195 Sutro Biopharma shares in Q3 2020, an estimated $2.81M.
  • Logos Global Management first reported a position in Sutro Biopharma in Q2 2020 and held it in 1 quarter.
  • Logos Global Management's Sutro Biopharma position peaked at $2.81M in Q2 2020.
  • 86 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2020.

Based on Logos Global Management's 13F filing for Q3 2020, filed 16 Nov 2020.